Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07492108 · ClinicalTrials.gov registry record · NA
Neuromodulation With Percutaneous Electrical Nerve Field Stimulation
A NA study, sponsored by The Cleveland Clinic.
- Active
- Registry status
- NA
- Development phase
- 140
- Enrollment target
NCT07492108 is a NA study that is active but no longer recruiting, run by The Cleveland Clinic. The registered enrollment target is 140 participants.
The verdict
NCT07492108, a NA study, is active but no longer recruiting, sponsored by The Cleveland Clinic.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 140 participants
- Enrollment target
Study Summary
The IB-Stim is the first device to be approved by the Food and Drug Administration (FDA) for the treatment of functional abdominal pain in adolescents aged 11-18 with IBS. However, the efficacy of Percutaneous electrical nerve field stimulation (PENFS) in adults with gastroparesis like symptoms (GPLS) is not currently known. This study is a double-blind, randomized, sham-controlled pilot study evaluating the efficacy of PENFS using IB-Stim in adult patients with GPLS. A secondary aim will be to assess whether treatment with PENFS is associated with changes in autonomic function via heart rate variability.
Interventions
- DEVICE Activated IB-Stim Device
- DEVICE Inactivated IB-Stim Device
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 140 participants |
| Start Date | 2026-01-08 |
| Est. Completion | 2027-08 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07492108
The ClinicalTrials.gov registry entry for NCT07492108 describes a study currently listed as active not recruiting, categorized as NA. The registered enrollment target is 140 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The Cleveland Clinic, which has 688 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Activated IB-Stim Device is the first listed.
NCT07492108 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07492108 about?
NCT07492108 is a clinical study titled "Neuromodulation With Percutaneous Electrical Nerve Field Stimulation". The IB-Stim is the first device to be approved by the Food and Drug Administration (FDA) for the treatment of functional abdominal pain in adolescents aged 11-18 with IBS. However, the efficacy of Percutaneous electrical nerve field stimulation (PENFS) in adults with gastroparesis like symptoms (GPL...
What is the current status of trial NCT07492108?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 140 participants. The study started on 2026-01-08. Estimated completion is 2027-08.
What interventions are being tested in trial NCT07492108?
The interventions under investigation include: Activated IB-Stim Device (DEVICE), Inactivated IB-Stim Device (DEVICE).
Who is sponsoring clinical trial NCT07492108?
This trial is sponsored by The Cleveland Clinic, which has 688 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.